NEW QIAstat-Dx Respiratory 2019-nCoV Panel 

NEW QIAstat-Dx Respiratory 2019-nCoV Panel 

December 18, 2020

To support the research efforts for accessible testing to meet the demands of the COVID-19 outbreak, QIAGEN® developed the QIAstat-Dx® Respiratory 2019-nCoV Panel. This version of our multiplex syndromic cartridge detects and differentiates 22 respiratory targets, including 2019-nCoV (SARS-CoV-2).

  • Includes 2 molecular targets specific to 2019-nCoV: ORF1b gene recommended by the Chinese Center for Disease Control and Prevention, and the E gene recommended by the US Centers for Disease Control and Prevention
  • Less than 1 minute hands-on time
  • Time to result: approximately 1 hour
New CFTR MASTR Dx validated for dried blood spots

New CFTR MASTR Dx validated for dried blood spots

Multiplicom is pleased to announce that CFTR MASTR™ Dx has been successfully validated for an additional sample type: dried blood spots. The CE-IVD claim is now extended to include DNA extracted from dried blood spots, allowing you to use the assay for routine neonatal screening.

March 12, 2015 More +
Ready to make an enquiry Call us on: + 961 1 39 66 77
Or email us